Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly, ImaginAb in Preclinical Immuno-oncology Alliance | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Lilly, ImaginAb in Preclinical Immuno-oncology Alliance

ImaginAb to use immune imaging agent to detect T-cell trafficking in Lilly molecules

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Eli Lilly and Co. and ImaginAb Inc. have entered preclinical research collaboration to study potential novel T-cell-based immuno-oncology therapies. Financial terms were not disclosed.

ImaginAb will conduct preclinical research using its immune imaging agent, IAB22M2C (a clinical anti-human CD8 probe), to detect T-cell trafficking, redirection and infiltration in response to Lilly oncology molecules. ImaginAb maintains full rights to its imaging agents used as part of the research project. 

CD8-positive T-cells, also known as cytotoxic T-cells, are associated with favorable clinical response to anti-PD-1 therapy in melanoma. IAB22M2C is a PET-based imaging agent that detects CD8-positive T-cells and provides a whole-body picture of immune response, potentially enabling better patient selection and mechanistic understanding of immune-modulating treatments.   

Lilly’s oncology pipeline comprises several molecules that impact the immune system, in addition to other agents directly targeting the tumor. These agents are being tested in a wide range of cancers, including breast, colorectal, gastric, skin, bladder, brain, pancreatic, liver and lung cancer.

“This collaboration demonstrates Lilly’s commitment to advancing biomarker-driven cancer therapies,” noted Greg Plowman, M.D., Ph.D., vice president of oncology research at Lilly. “ImaginAb has developed a highly specific and novel approach for visualizing a patient’s immune response, and we are excited to explore applications of this technology as part of our immuno-oncology drug development efforts.”

“Selecting the proper patients for immunotherapy continues to be a major challenge for the new wave of cancer therapies coming to market,” said Roger Crystal, M.D., chief business officer for ImaginAb. “Same-day CD8 imaging holds tremendous potential in helping to guide treatment for cancer immunotherapies, and we look forward to pioneering this approach with Lilly.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics